Mark Anderson
With a new year comes new opportunities for incredible start-ups to make their mark on the biotechnology industry. Within this burgeoning field, a number of innovative companies have already made strides in their research and development initiatives, despite days of the global pandemic. York, in particular, has become a hotspot for such start-ups. This article takes a moment to highlight some of the promising biotechnology firms that were established in 2020 or later and that areheadquartered in York.
Biotechnology has an enormous potential to address some of the most pressing health care challenges, especially in the areas of disease diagnosis, therapeutic treatment, and genetic health. The companies highlighted in this article are all sitting at the cutting edge of the biotechnology sector, exploiting new technologies, approaches, and ideas to improve and save lives. They are redefining the way we envision and interact with biological processes, from the smallest microbial organisms to complex human systems.
From immune monitoring platforms powered by artificial intelligence, to targeted nucleic acid therapeutics for unmet oncology and rare monogenic skeletal muscle diseases, these York start-ups are pushing the boundaries of current biotechnology and health care paradigms. Here’s a snapshot of the biotech startups creating a buzz in York:
Gameto
Committed to redefining female reproductive health, Gameto has set its vision on developing therapies that improve lives. Using cellular engineering, the company has developed a platform to produce female reproductive cell lines. Gameto’s first program, Fertilo, aims to make the process of IVF and egg freezing shorter, safer and more effective. Find them also on LinkedIn.
Linus Biotechnology
Linus Biotechnology focuses on a technology platform that builds on breakthroughs in exposome sequencing. It was founded in 2020 by Manish Arora and is headquartered in New York, United States. Connect with them on Linkedin.
Evvy
With a mission to radically reinvent how we understand and treat the female body, Evvy is taking on the vaginal microbiome. They empower anyone with a vagina to take control of their preventive health through their home testing kits. Their team includes scientists, designers, doctors, and entrepreneurs. Follow them on LinkedIn.
Treadwell Therapeutics
Treadwell Therapeutics is a clinical-stage oncology company developing medicines that address unmet needs in cancer patients. It has an internally developed pipeline that includes a first-in-class PLK4 kinase inhibitor, CFI-400945. Discover more on LinkedIn.
Ozette Technologies
Ozette is a life sciences data startup company that develops an artificial intelligence-enabled immune monitoring platform. The data can be used by doctors to diagnose and prescribe medication with greater accuracy. See their profile on LinkedIn.
Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. Learn more about them on LinkedIn.
76Bio
Developing therapies for life-threatening diseases, 76Bio specializes in pioneering targeted protein degraders. For more information, see their profile on LinkedIn.
Reset Pharmaceuticals
Reset Pharma focuses on the development and commercialization of novel psychedelic treatments for patients with life-threatening illnesses, including cancer. Visit their LinkedIn profile here.
BAKX Therapeutics
BAKX Therapeutics provides cutting-edge cancer treatments. To learn more about BAKX, check out their LinkedIn.
Graviton
Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. They are currently developing TDI01, a highly selective, potent inhibitor of ROCK2.
Nine Square Therapeutics
Nine Square Therapeutics is discovering new small-molecule therapeutics for degenerative movement disorders like Parkinson’s disease and amyotrophic lateral sclerosis (ALS), by integrating computational chemistry, biophysics, and computational biology into machine-learning-enabled cell profiling platforms.
While each of these startups has a unique research focus and business model, they share a common commitment to innovation and a vision for a healthier future. It will be exciting to see how these York-based newcomers continue to transform the biomedical landscape in the coming years.
